SYK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BUY now. Stryker just triggered an event-driven upside move (raised annual profit forecast; stock +4.31% regular session, holding ~369.6 post-market), and near-term momentum is improving (MACD expanding positive) despite the longer-term trend still being technically heavy (SMA_200 > SMA_20 > SMA_5). Options positioning is net bullish (put/call ratios below 1), and the latest quarter (2025/Q4) showed strong growth (revenue +11.4% YoY, EPS +56% YoY), supporting follow-through buying. Key drawback is supply/overhang risk: hedge funds and insiders have been selling recently, and price is approaching resistance (R1 ~371.6). Still, for an impatient buyer prioritizing immediate opportunity, the guidance-raise catalyst plus improving momentum makes this a good buy right now.
Intellectia Proprietary Trading Signals
Price action: big upside day (+4.31%) and holding gains post-market (~369.6), suggesting strong immediate demand after the forecast raise. Trend: still mixed-to-bearish on moving averages (SMA_200 > SMA_20 > SMA_5) = longer-term down/repair phase, even after today’s jump. Momentum: MACD histogram +0.327 and expanding = bullish momentum improving. RSI(6): ~69 = elevated/near overbought, so the stock is extended short-term but not screaming reversal by itself. Levels: Pivot ~361.9 is the near-term line in the sand; price is now close to R1 ~371.6 (next R2 ~377.7). A push through ~371–372 would be technically constructive; failure there could mean a quick retest toward the pivot zone.
drove a sharp upside move, which can attract momentum and upgrade-driven buying.
supports the revised outlook narrative.
Positioning/flows: Hedge funds are selling (selling amount +119.77% last quarter) and insiders are selling (selling amount +143.32% last month), which can cap rallies.
Technical overhead: price is nearing resistance around ~371–372 shortly after a gap-like move; RSI is elevated.
Analyst valuation concern: TD Cowen downgrade to Hold cites valuation and that the beat/raise pattern is already reflected, limiting “surprise upside.”
Latest quarter: 2025/Q4. Growth: Revenue $7.171B (+11.42% YoY) shows strong top-line demand. Profitability: Net income $849M (+55.49% YoY) and EPS 2.20 (+56.03% YoY) indicate meaningful operating leverage and/or mix improvement. Margin: Gross margin 61.9% (down 1.59% YoY) is the main blemish, but earnings growth suggests cost control/scale is still working in the income statement.
Recent trend: Mixed but leaning positive. There were several Outperform/Overweight reiterations/upgrades (Raymond James upgrade to Outperform $418; Citizens upgrade to Outperform $440; Bernstein Outperform $465; Wells Fargo Overweight $456), alongside more cautious calls (Goldman Neutral with target cut to $399; Truist Hold ~low-$390s; TD Cowen downgraded to Hold $387). Wall Street pros: high-quality MedTech compounder, strong procedure/procedure-related demand and pipeline, outlook for sustained organic growth and operating leverage. Wall Street cons: valuation seen as already pricing in the well-known beat/raise pattern; policy/rotation risk in healthcare; preference by some shops for faster near-term accelerators. Politicians/Congress: No recent congress trading data available in the last 90 days.
